| Date | Title | Description |
| 29.10.2025 | Earlybird Health promotes two new partners as firm deepens biotech and analytics focus | Life sciences investor Earlybird Health has promoted Dr. Rabab Nasrallah and Dr. Christoph Massner to Partners. Both new partners have led the firm's strategy across biotech, data-enabled therapeutics and medtech.
Earlybird Health, part of ... |
| 03.12.2024 | Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting | Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
Mocravimod is the only S1P receptor modulator being developed as an adjunct... |
| 18.06.2024 | EUROAPI and Priothera enter into CDMO collaboration to advance oncology project | Press Release
EUROAPI and Priothera, a biotechnology company specializing in the treatment of hematological malignancies and the improvement of CAR-T cell therapies, have signed a 5-year CDMO agreementEUROAPI will develop and industrialize ... |
| 22.04.2024 | Earlybird Health's ESG report one year on: how can VCs optimise for social impact? | With €2 billion of assets under management across all fund streams, nine IPOs and 33 trade sales, Earlybird VC is one of Europe’s most active venture capital firms.
Earlybird Health decided to supercharge its sustainability initiatives and ... |
| 14.02.2024 | Earlybird Health closes twice-larger second fund, will write bigger checks | Germany-based Earlybird Health announced the final closing of its second fund of €173 million (around $185 million). This is more than twice the size of Earlybird‘s first healthcare-focused fund, Health I, which reached €85 million at final... |
| 27.11.2023 |
US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies | Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers
Mocravimod is being investigated in a global registration-enabling Phase 3 trial
This is the second Orphan Drug des... |
| 24.01.2023 | Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoi... | Dublin, Ireland – January 23, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod today announced that the first patients have been enrolled in the pivot... |
| 23.01.2023 |
Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with AML undergoing allogeneic HCT | Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T therapy
Phase 1b/2a data has shown mocravimod is safe and well tolerated
Priothera, a late-clinical stage biotechnology company pioneering th... |
| 23.01.2023 | Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoi... | Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T therapy
Phase 1b/2a data has shown mocravimod is safe and well tolerated
DUBLIN, Jan. 23, 2023 /PRNewswire/ -- Priothera, a late-clinical stage b... |
| 01.06.2022 |
Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients | Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) ... |
| 25.04.2022 | Priothera to present an abstract at the TANDEM Meetings / Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR – April 23-26 2022
Conclusion | The success of allogeneic hematopoietic stem cell transplantation (HSCT) is limited by disease relapse. Alloreactive donor T cells have the potential to reject residual malignant cells and are essential to prevent relapse by graft-versus-le... |
| 25.04.2022 |
Priothera Receives FDA clearance of IND to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT) |
Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, today announces that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed w... |
| 12.04.2022 |
Priothera Receives First Regulatory Approvals to Start a Global Pivotal Study with Mocravimod in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant |
Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator mocravimod, today announces it has received the two first European country approvals from the Swiss and French national he... |
| 04.03.2022 |
Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)... |
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator drug, mocravimod, today announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) hav... |
| 23.02.2022 |
Priothera Enters Loan Agreement of €17.5 Million with the European Investment Bank |
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator drug, mocravimod, today announces that it has entered a Loan Agreement of €17.5 million with the European Investment Bank (EIB... |
| 25.11.2021 |
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer | Priothera Limited, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer. Dr. Kueenburg wi... |
| 13.10.2020 | Biotech startup Priothera lands €30M | Priothera, a Dublin-based developer of leukemia treatments, has raised €30 million in a Series A led by Fountain Healthcare Partners and HealthCap. The funds will be used for the clinical development of its lead therapy.
Additional Investor... |
| 12.10.2020 | Dublin-based biotech startup Priothera launches with $35.4 million Series A funding to develop treatments for patients suffering from leukemia | Priothera is a Dublin, Ireland-based biotech startup with a mission to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic He... |
| 12.10.2020 |
Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML) | Priothera Limited, a clinical stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies, today announced that it has successfully closed a Series A financing round of €30 milli... |
| 12.10.2020 | This Dublin-based startup raises €30M to develop promising therapies for leukemia | The global blood and bone marrow cancer treatment market was valued at $38.8B (approx €32.8B) in 2018 and is reportedly expected to reach $74.9B (approx €63.4B) by 2027, expanding at a CAGR of 7.7% from 2019 to 2027.
Blood cancer begins in ... |
| 12.10.2020 | Priothera Raises €30M in Series A Financing | Priothera, a Dublin, Ireland-based clinical stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies, closed a €30m Series A financing round.
The round was led by Fountain Hea... |
| 12.10.2020 | Priothera raises €30M to trial ex-Novartis' S1P drug in AML | Priothera has raised €30 million ($35 million) to fund clinical trials of a S1P receptor modulate once in development at Novartis. The drug, mocravimod, will undergo testing in high-risk acute myeloid leukemia (AML) patients who are undergo... |
| - | Priothera Receives First Regulatory Approvals to Start a Global Pivotal Study with Mocravimod in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant | Global Phase 2b/3 trial assessing the efficacy and safety of mocravimod as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HSCT planned to start in H2 202
Dublin, Ireland – 11th April 2022 – Priothera Ltd, a lat... |
| - | Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Tran... | Global Phase 2b/3 trial (MO-TRANS) assessing the efficacy and safety of mocravimod, a novel S1P receptor modulator, as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HSCT, planned to start in H2 2022.
Dublin, I... |
| - | Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer | Dr. Kueenburg, former Clinical Development Lead at Celgene, a Bristol Myers Squibb Company, to advance clinical development of mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic stem cell transplant.
Dublin, ... |
| - | Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Tran... | Global Phase 2b/3 trial (MO-TRANS) assessing the efficacy and safety of mocravimod, a novel S1P receptor modulator, as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HSCT, planned to start in H2 2022
Dublin, Ir... |
| - | Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) | Mocravimod is being developed as a potential best-in-class adjunctive and maintenance therapy to enhance the curative potential of HSCT for AML patients.
A global registration-enabling Phase 2b trial assessing mocravimod in AML patients und... |
| - | Priothera Enters Loan Agreement of €17.5 Million with the European Investment Bank | Loan will further support the conduct of a global registration-enabling clinical trial with mocravimod for the treatment of Acute Myeloid Leukemia, and for expansion into additional cancer indications.
Dublin, Ireland – 23 February 2022 – ... |
